Literature DB >> 30216223

Surgical Outcomes of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Korea-Japan Multicenter Study.

Dong-Sik Kim1, Bong-Wan Kim2, Etsuro Hatano3, Shin Hwang4, Kiyoshi Hasegawa5, Atsushi Kudo6, Shunichi Ariizumi7, Masaki Kaibori8, Takumi Fukumoto9, Hideo Baba10, Seong Hoon Kim11, Shoji Kubo12, Jong Man Kim13, Keun Soo Ahn14, Sae Byeol Choi1, Chi-Young Jeong15, Yasuo Shima16, Hiroaki Nagano17, Osamu Yamasaki18, Hee Chul Yu19, Dai Hoon Han20, Hyung-Il Seo21, Il-Young Park22, Kyung-Sook Yang23, Masakazu Yamamoto7, Hee-Jung Wang2.   

Abstract

OBJECTIVE: To identify optimal surgical methods and the risk factors for long-term survival in patients with hepatocellular carcinoma accompanied by macroscopic bile duct tumor thrombus (BDTT). SUMMARY BACKGROUND DATA: Prognoses of patients with hepatocellular carcinoma accompanied by BDTT have been known to be poor. There have been significant controversies regarding optimal surgical approaches and risk factors because of the low incidence and small number of cases in previous reports.
METHODS: Records of 257 patients from 32 centers in Korea and Japan (1992-2014) were analyzed for overall survival and recurrence rate using the Cox proportional hazard model.
RESULTS: Curative surgery was performed in 244 (94.9%) patients with an operative mortality of 5.1%. Overall survival and recurrence rate at 5 years was 43.6% and 74.2%, respectively. TNM Stage (P < 0.001) and the presence of fibrosis/cirrhosis (P = 0.002) were independent predictors of long-term survival in the Cox proportional hazards regression model. Both performing liver resection equal to or greater than hemihepatectomy and combined bile duct resection significantly increased overall survival [hazard ratio, HR = 0.61 (0.38-0.99); P = 0.044 and HR = 0.51 (0.31-0.84); P = 0.008, respectively] and decreased recurrence rate [HR = 0.59 (0.38-0.91); P = 0.018 and HR = 0.61 (0.42-0.89); P = 0.009, respectively].
CONCLUSIONS: Clinical outcomes were mostly influenced by tumor stage and underlying liver function, and the impact of BDTT to survival seemed less prominent than vascular invasion. Therefore, an aggressive surgical approach, including major liver resection combined with bile duct resection, to increase the chance of R0 resection is strongly recommended.

Entities:  

Mesh:

Year:  2020        PMID: 30216223     DOI: 10.1097/SLA.0000000000003014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  The benefit of curative liver resection with a selective bile duct preserving approach for hepatocellular carcinoma with macroscopic bile duct tumor thrombus.

Authors:  Anon Chotirosniramit; Akkaphod Liwattanakun; Sunhawit Junrungsee; Wasana Ko-Iam; Trichak Sandhu; Worakitti Lapisatepun
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

Review 2.  Overview of Complications in Cirrhosis.

Authors:  Madhumita Premkumar; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2022-05-14

3.  Portal modulation effects of terlipressin on liver regeneration and survival in a porcine model subjected to 90% hepatectomy.

Authors:  Hye-Sung Jo; Hyun-Jin Park; Yoon Young Choi; Jin-I Seok; Jae-Hyun Han; Young-In Yoon; Dong-Sik Kim
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 4.  Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.

Authors:  Jingxian Duan; Yuling Wu; Jikui Liu; Jiajia Zhang; Zhichao Fu; Tieshan Feng; Ming Liu; Jie Han; Zhicheng Li; Shifu Chen
Journal:  J Hepatocell Carcinoma       Date:  2019-10-18

5.  Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge.

Authors:  Xiaoqi Zhou; Jifei Wang; Mimi Tang; Mengqi Huang; Ling Xu; Zhenpeng Peng; Zi-Ping Li; Shi-Ting Feng
Journal:  BMC Cancer       Date:  2020-01-22       Impact factor: 4.430

6.  Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis.

Authors:  Jin-Kai Feng; Zhen-Hua Chen; Yu-Xuan Wu; Kang Wang; Ju-Xian Sun; Zong-Tao Chai; Wei-Xing Guo; Jie Shi; Shu-Qun Cheng
Journal:  Ann Transl Med       Date:  2020-12

7.  Should Lymph Nodes Be Retrieved in Patients with Intrahepatic Cholangiocarcinoma? A Collaborative Korea-Japan Study.

Authors:  Chang Moo Kang; Kyung-Suk Suh; Nam-Joon Yi; Tae Ho Hong; Sang Jae Park; Keun Soo Ahn; Hiroki Hayashi; Sae Byeol Choi; Chi-Young Jeong; Takeshi Takahara; Shigehiro Shiozaki; Young Hoon Roh; Hee Chul Yu; Takumi Fukumoto; Ryusei Matsuyama; Uyama Naoki; Kazuki Hashida; Hyung Il Seo; Takehiro Okabayashi; Tomoo Kitajima; Sohei Satoi; Hiroaki Nagano; Hongbeom Kim; Kaoru Taira; Shoji Kubo; Dong Wook Choi
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

8.  Hepatocellular Carcinoma with Portal Vein Tumor Thrombus versus Hepatocellular Carcinoma with Biliary Tumor Thrombus: Better or Worse Prognoses? [Letter].

Authors:  Jin-Kai Feng; Ju-Xian Sun; Zong-Han Liu; Shu-Qun Cheng
Journal:  Cancer Manag Res       Date:  2021-02-03       Impact factor: 3.989

9.  A staged approach with initial tumor thrombectomy followed by hepatectomy for icteric-type hepatocellular carcinoma: A case report.

Authors:  Takehisa Yazawa; Takehiro Ohta; Shun-Ichi Ariizumi; Yutaka Takahashi; Ryota Higuchi; Masakazu Yamamoto
Journal:  Int J Surg Case Rep       Date:  2019-09-27

10.  Exploring new pathways in the treatment of hepatocellular cancer.

Authors:  Łukasz Masior; Michał Grąt
Journal:  Ann Transl Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.